Stock IPSC CENTURY THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Century Therapeutics, Inc.

Equities

IPSC

US15673T1007

Market Closed - Nasdaq
Other stock markets
 16:00:00 2024-05-14 EDT 		5-day change 1st Jan Change
3.15 USD +5.00% Intraday chart for Century Therapeutics, Inc. -6.53% -5.12%
05-10 Century Therapeutics Presents Preclinical Data Highlighting Advances in Ipsc Platform Technology and Programs At 2024 Asgct Annual Meeting CI
05-09 Century Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Century Therapeutics Presents Preclinical Data Highlighting Advances in iPSC Platform Technology and Programs at 2024 ASGCT Annual Meeting
AQ
Century Therapeutics Presents Preclinical Data Highlighting Advances in iPSC Platform Technology and Programs at 2024 ASGCT Annual Meeting
GL
Century Therapeutics Presents Preclinical Data Highlighting Advances in Ipsc Platform Technology and Programs At 2024 Asgct Annual Meeting
CI
Century Therapeutics : Corporate Overview May 2024
PU
Century Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates
GL
Century Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Century Therapeutics to Present at Chardan's 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit
AQ
Century Therapeutics to Present at Chardan’s 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit
GL
Century Therapeutics to Present at Chardan’s 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit
AQ
Piper Sandler Adjusts Price Target on Century Therapeutics to $9 From $10, Maintains Overweight Rating
MT
Syncona agrees to sell stake in investee company for GBP7.4 million
AN
Syncona to Sell Stake in Portfolio Company to Century Therapeutics
MT
Century Therapeutics Strengthens Position in Autoimmune Disease with Strategic Pipeline Expansion Supported by $60 Million Private Placement and Acquisition of Clade Therapeutics
GL
Century Therapeutics Announces Plans to Expand Clinical Development for Its Lead Program, CNTY-101
CI
Century Therapeutics, Inc. acquired Clade Therapeutics, Inc. from Syncona Limited for $45 million..
CI
Century Therapeutics, Inc. announced that it expects to receive $59.999982 million in funding from a group of investors
CI
Century Therapeutics, Inc. agreed to acquire Clade Therapeutics, Inc. from Syncona Limited for $45 million.
CI
Century Therapeutics Presents New Preclinical Data Highlighting iPSC-derived Cell Therapy Platform Technology at the 2024 American Association for Cancer Research Annual Meeting
CI
Century Therapeutics Presents New Preclinical Data Highlighting iPSC-derived Cell Therapy Platform Technology at the 2024 American Association for Cancer Research (AACR) Annual Meeting
GL
Century Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference
GL
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. IPSC Stock
  4. News Century Therapeutics, Inc.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW